Article
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2013
Tsai Chun-Ming, Chen Jen-Ting, Chiu Chao-Hua, Lai Chun-Liang, Hsiao Shih-Yin, Chang Kuo-Ting
Abstract excerpt
BACKGROUND: Combined epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with chemotherapy is believed to be more effective in treating non-small-cell lung cancer (NSCLC) with sensitizing-EGFR mutation (SEM). This hypothesis failed to be realized clinically and needs to be examined in vitro. MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.